Clinical Trial Update: Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

A Phase III clinical trial is testing EBV-DNA-guided adaptive immunotherapy for advanced nasopharyngeal carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• EBV-DNA-Guided Adaptive Immunotherapy

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | Phase 3 | Status: NOT_YET_RECRUITING